Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 143 No. 3536 (2013)

Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients

  • SHENG-WEN WU
  • Hui-Ching Tsai
  • Pao-Yu Tsai
  • Tung-Wei Hung
  • Horng-Rong Chang
  • Jong-Da Lian
DOI
https://doi.org/10.4414/smw.2013.13850
Cite this as:
Swiss Med Wkly. 2013;143:w13850
Published
25.08.2013

Summary

PRINCIPLES: The once-daily tacrolimus formulation (Advagraf®), with the potential for improving medical adherence, has been advocated to improve long-term kidney allograft outcomes. However, experience with late conversion from the twice-daily tacrolimus formulation (Prograf®) to Advagraf in the daily care of stable kidney transplant recipients has been limited.

METHODS: The aim of this study was to observe the efficacy and safety of conversion from Prograf to Advagraf in chronic stable kidney transplant recipients in routine clinical practice. The recruited patients had postconversion follow-up at least once monthly for a total of six months, unless they had discontinued the use of Advagraf, had been lost the follow-up or had lost the graft.

RESULTS: The mean age of the 199 patients was 51.5 ± 10.4 years (60.8% male). The mean time from transplantation to the conversion to Advagraf was 8.3 ± 3.2 years and the mean tacrolimus trough level at conversion was 4.2 ± 1.4 ng/ml. After conversion, 147 patients (73.8 %) had a reduced trough level at one month and the mean change in trough level postconversion was –13.5%. The mean serum creatinine level between conversion and six months postconversion was not significantly different (1.12 ± 0.36 vs 1.10 ± 0.42 mg/dl). Thirty-four patients (17%) discontinued the treatment with Advagraf and two (1%) developed biopsy-proved acute rejection.

CONCLUSIONS: In conclusion, frequent conversion caused by a high discontinuation rate may further raise the potential risk of allograft rejection and increase unnecessary cost. In view of this, the policy of converting to Advagraf with the purpose of improving medical adherence should be individualised in routine clinical practice.

References

  1. Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. General hospital psychiatry. 2000;22(6):412–24.
  2. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clinical journal of the American Society of Nephrology: CJASN. 2010;5(7):1305–11.
  3. Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4(4):621–5.
  4. Chisholm MA, Middleton MD. Modified-release tacrolimus. The Annals of pharmacotherapy. 2006;40(2):270–5.
  5. Kramer BK, Charpentier B, Backman L, Silva HT, Jr., Mondragon-Ramirez G, Cassuto-Viguier E, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010;10(12):2632–43.
  6. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007;83(12):1648–51.
  7. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation. 2010;90(5):523–9.
  8. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le Moine A, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011;91(5):566–9.
  9. Tinti F, Mecule A, Poli L, Bachetoni A, Umbro I, Brunini F, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplantation proceedings. 2010;42(10):4047–8.
  10. Guirado L, Cantarell C, Franco A, Huertas EG, Fructuoso AS, Fernandez A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2011;11(9):1965–71.
  11. Hougardy JM, de Jonge H, Kuypers D, Abramowicz D. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? Transplantation. 2012;93(3):241–3.
  12. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs. 2011;71(12):1561–77.
  13. Wu MJ, Cheng CY, Chen CH, Wu WP, Cheng CH, Yu DM, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation. 2011;92(6):648–52.
  14. Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, Martinez-Fernandez G, Perez-Martinez J, Gomez-Roldan C. Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplantation proceedings. 2009;41(6):2326–7.
  15. Iaria G, Sforza D, Angelico R, Toti L, de Luca L, Manuelli M, et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. Transplantation proceedings. 2011;43(4):1028–9.
  16. Diez Ojea B, Alonso Alvarez M, Aguado Fernandez S, Banos Gallardo M, Garcia Melendreras S, Gomez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplantation proceedings. 2009;41(6):2323–5.
  17. Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenetics and genomics. 2011;21(4):179–84.
  18. Mecule A, Poli L, Nofroni I, Bachetoni A, Tinti F, Umbro I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplantation proceedings. 2010;42(4):1317–9.
  19. Weng FL, Israni AK, Joffe MM, Hoy T, Gaughan CA, Newman M, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. Journal of the American Society of Nephrology: JASN. 2005;16(6):1839–48.
  20. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77(5):769–76.
  21. Takemoto SK, Pinsky BW, Schnitzler MA, Lentine KL, Willoughby LM, Burroughs TE, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007;7(12):2704–11.
  22. Beckebaum S, Iacob S, Sweid D, Sotiropoulos GC, Saner F, Kaiser G, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transplant international: official journal of the European Society for Organ Transplantation. 2011;24(7):666–75.